Skip to main navigation
Skip to search
Skip to main content
Edge Hill University Home
Help & FAQ
Link opens in a new tab
Search content at Edge Hill University
Home
Profiles
Research units
Research output
Projects
Student theses
Activities
Prizes
Impacts
Equipment
Datasets
Intermittent prophylactic antibiotics for bronchiectasis
SALLY SPENCER
, Tim Donovan
, James Chalmers
, Alexander Mathioudakis
, Melissa McDonnell
, ANTHONY TSANG
, PETER LEADBETTER
Medical School
University of Cumbria
University of Dundee
University of Manchester
Saolta University Health Care Group
Research output
:
Contribution to journal
›
Article (journal)
›
peer-review
16
Link opens in a new tab
Citations (Scopus)
373
Downloads (Pure)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Intermittent prophylactic antibiotics for bronchiectasis'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Absence of Evidence
12%
Adverse Effects
37%
Airway
25%
Allergic Bronchopulmonary Aspergillosis
12%
Aminoglycosides
12%
Antibiotic Regimen
37%
Antibiotic Resistance
75%
Antibiotic Therapy
12%
Antibiotic Treatment
12%
Antibiotics
100%
Beneficial Outcomes
12%
Beta-lactams
12%
Bronchiectasis
100%
Bronchography
12%
Chest Infection
12%
Chest Radiograph
12%
Chronic Disorders
12%
Ciprofloxacin
12%
Clinical Diagnosis
12%
Clinical Practice Guidelines
12%
Cochrane
25%
Continuous Data
12%
Cystic Fibrosis
12%
Dichotomous Data
12%
Electronic Search
12%
Event Rate
12%
Event Time
12%
Exacerbation Rate
62%
Fluoroquinolones
25%
Forced Expiratory Volume in 1 Second (FEV1)
25%
Grade Estimation
12%
Health-related Quality of Life
50%
High Dose
12%
High-resolution Computed Tomography
12%
Hospital Admission
25%
Hypogammaglobulinemia
12%
Inconsistency
12%
Infection Cycle
12%
Intermittent Regime
12%
Intermittent Regimen
12%
Lack of Evidence
12%
Life Effects
25%
Low Risk
12%
Lung Function
37%
Methodological Procedures
12%
Odds Ratio
62%
Persistent Cough
12%
Phlegmon
12%
Placebo
50%
Plain Film
12%
Pooled Analysis
12%
Potential Gains
12%
Potential Risk
12%
Primary Ciliary Dyskinesia
12%
Primary Diagnosis
12%
Prophylactic Administration
12%
Prophylactic Antibiotics
100%
Publication Language
12%
Quality of Life
12%
Randomized Controlled Trial
25%
Recurrent Chest Infection
12%
Recurrent Infections
12%
Recurrent Inflammation
12%
Relative Risk
50%
Repeated Courses
12%
Risk Data
12%
Risk of Bias
12%
Sarcoidosis
12%
Serious Adverse Events
75%
Severe Exacerbation
12%
Standardized Mean Difference
12%
Treatment Regimen
12%
Trial Registries
12%
Usual Care
37%
Nursing and Health Professions
Accident Prevention
33%
Adverse Effect
50%
Adverse Event
100%
Allergic Bronchopulmonary Aspergillosis
16%
Aminoglycoside
16%
Antibiotic Resistance
100%
Antibiotic Therapy
50%
Antimicrobial Agent
100%
Bronchiectasis
100%
Bronchography
16%
Chest Infection
33%
Ciliary Dyskinesia
16%
Ciprofloxacin
16%
Clinical Guideline
16%
Computer Assisted Tomography
16%
Coughing
16%
Cystic Fibrosis
16%
Diseases
16%
Drug Megadose
16%
Efficacy
33%
Film
16%
Immunoglobulin Deficiency
16%
Infection
33%
Inflammation
16%
Lactam
16%
Obstructive Lung Disease
16%
Odds Ratio
83%
Placebo
66%
Quality of Life
83%
Quinolone Derivative
33%
Recurrent Infection
16%
Sarcoidosis
16%
Thorax Radiography
16%
Medicine and Dentistry
Adverse Effect
37%
Adverse Event
75%
Allergic Bronchopulmonary Aspergillosis
12%
Aminoglycoside
12%
Antibiotic Resistance
75%
Antibiotic Therapy
37%
Antibiotics
100%
Antimicrobial Agent
75%
Bronchiectasis
100%
Bronchography
12%
Chest Infection
25%
Chronic Disorder
12%
Chronic Obstructive Pulmonary Disease
12%
Ciprofloxacin
12%
Clinical Guideline
12%
Coughing
12%
Cystic Fibrosis
12%
Drug Megadose
12%
High-Resolution Computed Tomography
12%
Hypogammaglobulinemia
12%
Infection
25%
Inflammation
12%
Lactam
12%
Lung
37%
Odds Ratio
62%
Placebo
50%
Pooled Analysis
12%
Primary Ciliary Dyskinesia
12%
Quality of Life
62%
Quinolone Derivative
25%
Randomized Controlled Trial
25%
Recurrent Infection
12%
Sarcoidosis
12%
Thorax Radiography
12%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Effect
37%
Adverse Event
75%
Allergic Bronchopulmonary Aspergillosis
12%
Aminoglycoside
12%
Antibiotic Resistance
75%
Antibiotic Therapy
25%
Antibiotics
100%
Antimicrobial Agent
87%
Bronchiectasis
100%
Chest Infection
25%
Chronic Obstructive Lung Disease
12%
Ciliary Dyskinesia
12%
Ciprofloxacin
12%
Coughing
12%
Cystic Fibrosis
12%
Diseases
12%
Immunoglobulin Deficiency
12%
Infection
25%
Inflammation
12%
Lactam
12%
Placebo
50%
Quinolone Derivative
25%
Randomized Controlled Trial
25%
Recurrent Infection
12%
Sarcoidosis
12%
Immunology and Microbiology
Adverse Effect
33%
Airway
22%
Allergic Bronchopulmonary Aspergillosis
11%
Antibiotic Resistance
66%
Antimicrobial Agent
100%
Computer Assisted Tomography
11%
Drug Megadose
11%
Hypogammaglobulinemia
11%
Infection
55%
Infectious Disease
55%
Inflammation
11%
Lung
33%
Sarcoidosis
11%